POLYMORPHIC FORMS OF ST-246 AND METHODS OF PREPARATION
Polymorph forms of 4-trifluoromethyl-N-(3,3a,4,4a,5,5a,6,6a-octahydro-1,3-dioxo-4,6-ethenocycloprop[f]isoindol-2 (1H)-yl)-benzamide are disclosed as well as their methods of synthesis and pharmaceutical compositions.
1 - 116 . (canceled)
117 . A method of treating Orthopoxvirus infections comprising administering to a subject in need thereof a therapeutically effective amount of a polymorph Form IV of 4-trifluoromethyl-N-(3,3a,4,4a,5,5a,6,6a-octahydro-1,3-dioxo-4,6-ethenocycloprop[f]isoindol-2(1H)-benzamide (ST-246) which shows an X-ray powder diffraction pattern having characteristic peaks at a reflection angle 20 of 6.97, 9.75, 11.21, 12.13, 13.54, 16.82, 18.17, 18.79, 19.69, 20.51, 23.31, 24.78, 27.24, 30.20, and 33.52 degrees.
118 . The method of claim 117 , wherein the polymorph Form IV is at least about 70% free of other forms.
119 . The method of claim 117 , wherein the polymorph Form I is at least about 80% free of other forms.
120 . The method of claim 117 , wherein the polymorph Form IV is at least about 90% free of other forms.
121 . The method of claim 117 , wherein the polymorph Form IV is at least about 95% free of other forms.
122 . The method of claim 117 , wherein the polymorph Form IV is at least about 99% free of other forms.
123 . The method of claim 117 , wherein the polymorph Form IV is administered orally.
124 . A method of treating eczema vaccinatum comprising administering to a patient in need thereof a therapeutically effective amount of a polymorph Form IV of 4-trifluoromethyl-N-(3,3a,4,4a,5,5a,6,6a-octahydro-1,3-dioxo-4,6-ethenocycloprop[f]isoindol-2(1H)-benzamide (ST-246) which shows an X-ray powder diffraction pattern having characteristic peaks at a reflection angle 20 of 6.97, 9.75, 11.21, 12.13, 13.54, 16.82, 18.17, 18.79, 19.69, 20.51, 23.31, 24.78, 27.24, 30.20, and 33.52 degrees.